Literature DB >> 8888702

Relationship between pretreatment viremia level and response to interferon-alpha therapy in chronic hepatitis C differs in viral type 1 and 2 infections.

A Tsubota1, H Kumada, K Chayama, Y Arase, S Saitoh, I Koida, N Murashima, Y Suzuki, M Kobayashi, K Takagi, M Kobayashi, K Ikeda.   

Abstract

To determine the contribution of virus-related factors to long-term remission of chronic hepatitis C infection, we analyzed viral type and viremia level in 185 patients who had undergone a six-month course of interferon-alpha therapy. These virus-related factors were measured by an enzyme-linked immunosorbent assay with use of viral type-specific antigens and the branched DNA (bDNA) signal amplification assay, respectively. Sustained and long-term sustained responses were achieved in 55% and 50% of the patients, respectively. Transient or no responses were observed in 30% and 15% of the patients, respectively. Thirty-five percent of viral type 1 patients and 82% of viral type 2 patients had long-term sustained responses. Forty-two percent of bDNA-positive and 71% of bDNA-negative patients experienced long-term sustained responses. On multivariate analysis, viral type, Knodell's intralobular score, and viremia level were strong independent predictors of long-term sustained response (P < 0.0001, = 0.0060, and 0.037, respectively). Viremia level, however, was a significant predictor only in viral type 1, not type 2, patients. The relation between pretreatment viremia level and response to interferon-alpha therapy in chronic hepatitis C differs in viral type 1 and 2 infections.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8888702     DOI: 10.1007/bf02093591

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  22 in total

1.  Implications of variations of "conserved" regions of hepatitis C virus genome.

Authors:  J Y Lau; P Simmonds; M S Urdea
Journal:  Lancet       Date:  1995-08-12       Impact factor: 79.321

2.  Randomized controlled trial of recombinant alpha-2a-interferon for chronic hepatitis C. Comparison of alanine aminotransferase normalization versus loss of HCV RNA and anti-HCV IgM.

Authors:  D D Douglas; J Rakela; H J Lin; F B Hollinger; H F Taswell; A J Czaja; J B Gross; M L Anderson; K Parent; C R Fleming
Journal:  Dig Dis Sci       Date:  1993-04       Impact factor: 3.199

3.  Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial.

Authors:  G L Davis; L A Balart; E R Schiff; K Lindsay; H C Bodenheimer; R P Perrillo; W Carey; I M Jacobson; J Payne; J L Dienstag
Journal:  N Engl J Med       Date:  1989-11-30       Impact factor: 91.245

4.  Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial.

Authors:  A M Di Bisceglie; P Martin; C Kassianides; M Lisker-Melman; L Murray; J Waggoner; Z Goodman; S M Banks; J H Hoofnagle
Journal:  N Engl J Med       Date:  1989-11-30       Impact factor: 91.245

5.  Effect of interferon administration on serum hepatitis C virus RNA in patients with chronic hepatitis C.

Authors:  K Chayama; S Saitoh; Y Arase; K Ikeda; T Matsumoto; Y Sakai; M Kobayashi; M Unakami; T Morinaga; H Kumada
Journal:  Hepatology       Date:  1991-06       Impact factor: 17.425

6.  Randomized, double-blind, placebo-controlled trial of eight-week course of recombinant alpha-interferon for chronic non-A, non-B hepatitis.

Authors:  M Omata; Y Ito; O Yokosuka; F Imazeki; M Tagawa; S Takano; K Hosoda; M Tada; M Ohto; K Ito
Journal:  Dig Dis Sci       Date:  1991-09       Impact factor: 3.199

7.  Factors useful in predicting the response to interferon therapy in chronic hepatitis C.

Authors:  A Tsubota; K Chayama; Y Arase; I Koida; S Saitoh; K Ikeda; S Iwasaki; T Matsumoto; M Kobayashi; H Kumada
Journal:  J Gastroenterol Hepatol       Date:  1993 Nov-Dec       Impact factor: 4.029

8.  Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha therapy: relationship to genotypes of hepatitis C virus.

Authors:  K Yoshioka; S Kakumu; T Wakita; T Ishikawa; Y Itoh; M Takayanagi; Y Higashi; M Shibata; T Morishima
Journal:  Hepatology       Date:  1992-08       Impact factor: 17.425

9.  Clinical backgrounds of the patients having different types of hepatitis C virus genomes.

Authors:  N Takada; S Takase; N Enomoto; A Takada; T Date
Journal:  J Hepatol       Date:  1992-01       Impact factor: 25.083

Review 10.  Variability of hepatitis C virus.

Authors:  P Simmonds
Journal:  Hepatology       Date:  1995-02       Impact factor: 17.425

View more
  3 in total

Review 1.  Peginterferon and ribavirin treatment for hepatitis C virus infection.

Authors:  Akihito Tsubota; Kiyotaka Fujise; Yoshihisa Namiki; Norio Tada
Journal:  World J Gastroenterol       Date:  2011-01-28       Impact factor: 5.742

2.  Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C.

Authors:  Haruya Ishiguro; Hiroshi Abe; Nobuyoshi Seki; Tomonori Sugita; Yuta Aida; Munenori Itagaki; Satoshi Sutoh; Noritomo Shimada; Tomomi Furihata; Akihito Tsubota; Yoshio Aizawa
Journal:  World J Gastroenterol       Date:  2015-04-07       Impact factor: 5.742

3.  Four-week pegylated interferon alpha-2a monotherapy for chronic hepatitis C with genotype 2 and low viral load: a pilot, randomized study.

Authors:  Akihito Tsubota; Ken-ichi Satoh; Mashu Aizawa; Seishi Takamatsu; Yoshihisa Namiki; Toshifumi Ohkusa; Kiyotaka Fujise; Hisao Tajiri
Journal:  World J Gastroenterol       Date:  2008-12-21       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.